These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24743031)

  • 1. The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3.
    Qin C; He B; Dai W; Lin Z; Zhang H; Wang X; Wang J; Zhang X; Wang G; Yin L; Zhang Q
    Biomaterials; 2014 Jul; 35(22):5908-20. PubMed ID: 24743031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
    Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
    J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of metastatic tumor growth and metastasis via targeting metastatic breast cancer by chlorotoxin-modified liposomes.
    Qin C; He B; Dai W; Zhang H; Wang X; Wang J; Zhang X; Wang G; Yin L; Zhang Q
    Mol Pharm; 2014 Oct; 11(10):3233-41. PubMed ID: 24559485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Silico prediction of the molecular basis of ClTx and AaCTx interaction with matrix metalloproteinase-2 (MMP-2) to inhibit glioma cell invasion.
    Othman H; Wieninger SA; ElAyeb M; Nilges M; Srairi-Abid N
    J Biomol Struct Dyn; 2017 Oct; 35(13):2815-2829. PubMed ID: 27678152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorotoxin-modified stealth liposomes encapsulating levodopa for the targeting delivery against Parkinson's disease in the MPTP-induced mice model.
    Xiang Y; Wu Q; Liang L; Wang X; Wang J; Zhang X; Pu X; Zhang Q
    J Drug Target; 2012 Jan; 20(1):67-75. PubMed ID: 22149216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2.
    Deshane J; Garner CC; Sontheimer H
    J Biol Chem; 2003 Feb; 278(6):4135-44. PubMed ID: 12454020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropilin-1 drives tumor-specific uptake of chlorotoxin.
    McGonigle S; Majumder U; Kolber-Simonds D; Wu J; Hart A; Noland T; TenDyke K; Custar D; Li D; Du H; Postema MHD; Lai WG; Twine NC; Woodall-Jappe M; Nomoto K
    Cell Commun Signal; 2019 Jun; 17(1):67. PubMed ID: 31208428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Combined Approach Employing Chlorotoxin-Nanovectors and Low Dose Radiation To Reach Infiltrating Tumor Niches in Glioblastoma.
    Tamborini M; Locatelli E; Rasile M; Monaco I; Rodighiero S; Corradini I; Franchini MC; Passoni L; Matteoli M
    ACS Nano; 2016 Feb; 10(2):2509-20. PubMed ID: 26745323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin.
    Lyons SA; O'Neal J; Sontheimer H
    Glia; 2002 Aug; 39(2):162-73. PubMed ID: 12112367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synergistic effect of chlorotoxin-mApoE in boosting drug-loaded liposomes across the BBB.
    Formicola B; Dal Magro R; Montefusco-Pereira CV; Lehr CM; Koch M; Russo L; Grasso G; Deriu MA; Danani A; Bourdoulous S; Re F
    J Nanobiotechnology; 2019 Nov; 17(1):115. PubMed ID: 31711496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas.
    Yang ZZ; Li JQ; Wang ZZ; Dong DW; Qi XR
    Biomaterials; 2014 Jun; 35(19):5226-39. PubMed ID: 24695093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of IRDye 800CW chlorotoxin as a targeting agent for brain tumors.
    Kovar JL; Curtis E; Othman SF; Simpson MA; Olive DM
    Anal Biochem; 2013 Sep; 440(2):212-9. PubMed ID: 23711726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A model of BmK CT in inhibiting glioma cell migration via matrix metalloproteinase-2 from experimental and molecular dynamics simulation study.
    Fu YJ; An N; Chan KG; Wu YB; Zheng SH; Liang AH
    Biotechnol Lett; 2011 Jul; 33(7):1309-17. PubMed ID: 21424168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
    Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
    Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous liposome membranes with pH-triggered permeability enhance the in vitro antitumor activity of folate-receptor targeted liposomal doxorubicin.
    Mamasheva E; O'Donnell C; Bandekar A; Sofou S
    Mol Pharm; 2011 Dec; 8(6):2224-32. PubMed ID: 21899300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlorotoxin-Fc fusion inhibits release of MMP-2 from pancreatic cancer cells.
    El-Ghlban S; Kasai T; Shigehiro T; Yin HX; Sekhar S; Ida M; Sanchez A; Mizutani A; Kudoh T; Murakami H; Seno M
    Biomed Res Int; 2014; 2014():152659. PubMed ID: 24511528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells.
    Kobayashi T; Ishida T; Okada Y; Ise S; Harashima H; Kiwada H
    Int J Pharm; 2007 Feb; 329(1-2):94-102. PubMed ID: 16997518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
    Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
    Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
    Zhang Q; Tang J; Fu L; Ran R; Liu Y; Yuan M; He Q
    Biomaterials; 2013 Oct; 34(32):7980-93. PubMed ID: 23891517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
    Gu G; Xia H; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Chen H; Gao X; Chen J
    Biomaterials; 2013 Jan; 34(1):196-208. PubMed ID: 23069707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.